Drug control of india served notice to SERUM to stop covid vaccine COVISHIELD’s trial in India. So Serum Institute of India, which is manufacturing the coronavirus vaccine Covishield being developed by the Oxford University along with pharma major AstraZenca, today said it will stop the Phase 3 trials that were to begin in India next week. Trial of the vaccine was stopped across four nations as a precautionary measure after one of the recipients in the UK showed some potentially adverse symptoms. “We are going by DCGI’s direction and so far were not told to pause the trials. If DCGI has any safety concerns, we will follow their instructions and abide by the standard protocols.” Said SERUM.